Compare IBTA & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBTA | PHAR |
|---|---|---|
| Founded | 2011 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 830.3M | 793.4M |
| IPO Year | 2024 | 2020 |
| Metric | IBTA | PHAR |
|---|---|---|
| Price | $57.81 | $13.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $50.57 | $35.70 |
| AVG Volume (30 Days) | ★ 456.8K | 15.1K |
| Earning Date | 11-02-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $342,389,000.00 | N/A |
| Revenue This Year | $7.08 | $2.98 |
| Revenue Next Year | $7.08 | $8.95 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.10 | $9.11 |
| 52 Week High | $66.39 | $21.34 |
| Indicator | IBTA | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 64.10 | 66.74 |
| Support Level | $36.20 | $11.83 |
| Resistance Level | $66.39 | $13.51 |
| Average True Range (ATR) | 3.70 | 0.49 |
| MACD | 0.16 | 0.10 |
| Stochastic Oscillator | 54.38 | 76.29 |
Ibotta Inc operates a digital promotions platform, the Ibotta Performance Network (IPN), which connects consumer packaged goods (CPG) brands with consumers through a network of publishers. It sources digital offers from clients and distributes them via its technology platform, earning revenue when promotions result in consumer transactions. The platform supports offers across grocery and general merchandise categories, including toys, clothing, beauty, electronics, pet, and home products. The majority of its revenues is derived from the fees charged to clients when consumers redeem offers on the IPN by purchasing promoted products.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.